New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?

Cells

Liang Cheng¹  Antonio Lopez-Beltran²  Francesco Massari³  Franco Nolè⁴  Gaetano Aurilio⁴  Matteo Santoni⁵  Marina Scarpelli⁶  Alessia Cimadamore⁶  Rodolfo Montironi⁶ 

[1] Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA;Department of Surgery, Cordoba University Medical School, 14071 Cordoba, Spain;Division of Oncology, S. Orsola-Malpighi Hospital, 40138 Bologna, Italy;Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy;Oncology Unit, Macerata Hospital, 62012 Macerata, Italy;Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, 60126 Ancona, Italy;

关键词: prostate cancer;    metastatic castration-resistant prostate cancer;    DNA damage repair;    ARS inhibitors;    PARP inhibitors;    immune checkpoint inhibitors;   

DOI  :  10.3390/cells9061522

来源: DOAJ

【 摘 要 】

Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in fact increasingly focusing on developing DNA damage repair (DDR) defect-driven novel molecules, both as single-agent therapy and in combined treatment strategies. Accordingly, research is under way into combined drug therapies targeting different pathways, e.g. androgen receptor signaling (ARS) and poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) enzymes, immune checkpoint (IC) and PARP, IC, and ARS, and prostate-specific membrane antigen (PSMA). In an attempt to formulate evolving treatment paradigms in mCRPC patients, here we selected clinical research into patients undergoing therapies with emerging molecules, with particular emphasis towards PARP-, IC-, and PSMA-inhibitors. In order to focus on those molecules and drug combinations most likely to be translated into routine clinical care in the near future, we selected only those clinical studies currently recruiting patients. A PubMed search focusing on the keywords “prostate cancer”, “metastatic castration-resistant prostate cancer”, “DDR pathways”, “ARS inhibitors”, “PARP inhibitors”, “IC inhibitors”, “PSMA-targeting agents”, and “drug combinations” was performed.

【 授权许可】

Unknown